Cargando…

4168 Understanding ECM-Based Drug Resistivity in Breast Cancer

OBJECTIVES/GOALS: Cell-cell (CC) and cell-matrix interactions (CM) are known to affect drug sensitivity of cancer cells, but are not effectively recapitulated using 2D platforms. This research aims to determine how cell and matrix interactions confer drug resistivity in 3 distinct culturing models:...

Descripción completa

Detalles Bibliográficos
Autores principales: Libring, Sarah, Shinde, Aparna, Boodaghidizaji, Miad, Plummer, Alexandra, Ardekani, Arezoo, Wendt, Michael, Solorio, Luis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8823421/
http://dx.doi.org/10.1017/cts.2020.346
_version_ 1784646798752612352
author Libring, Sarah
Shinde, Aparna
Boodaghidizaji, Miad
Plummer, Alexandra
Ardekani, Arezoo
Wendt, Michael
Solorio, Luis
author_facet Libring, Sarah
Shinde, Aparna
Boodaghidizaji, Miad
Plummer, Alexandra
Ardekani, Arezoo
Wendt, Michael
Solorio, Luis
author_sort Libring, Sarah
collection PubMed
description OBJECTIVES/GOALS: Cell-cell (CC) and cell-matrix interactions (CM) are known to affect drug sensitivity of cancer cells, but are not effectively recapitulated using 2D platforms. This research aims to determine how cell and matrix interactions confer drug resistivity in 3 distinct culturing models: 2D (no CM/limited CC), 3D spheroids (CC) and 3D fibronectin (both). METHODS/STUDY POPULATION: We examined four breast cancer cell types. The cells were derived from a nonmetastatic primary tumor (HMLE-E2) or overt bone-metastasis (BM). Transglutaminase 2 (TGM2), a matrix crosslinking protein, is overexpressed in metastatic bone tumors and may play a key role in matrix-conferred drug resistivity. In a gain-of-function model, TGM2 was upregulated in HMLE-E2 cells and compared to shTGM2 knockdown BM cells. Growth rates were analyzed using metabolic activity over 8 days, and drug sensitivity to Neratinib (0-1000 nM) was analyzed via cell titer. To account for the different transport properties of the 3 distinct culture environments, we developed a mathematical model for each condition, allowing us to normalize the drug sensitivity results across models to effectively compare true biological resistivity. RESULTS/ANTICIPATED RESULTS: We observed that increased cellular levels of TGM2 significantly increase the growth rate and drug resistivity of cells on fibronectin matrices. Interestingly, in 2D cultures, TGM2 expression was correlated with higher Neratinib resistivity but did not affect growth rates. In spheroid models without a significant matrix component, that rely solely on cell-cell junctions, high levels of TGM2 were correlated with lower survival rates. Lower levels of TGM2 are correlated with a more epithelial phenotype, and using our mathematical model we have identified significant transport differences between high and low TGM2 spheroids. We theorize that the low TGM2 spheroids have denser packing, which lowers the rate of diffusion and, thus reduces the effective concentration of the drug to the majority of the cells. DISCUSSION/SIGNIFICANCE OF IMPACT: Our studies indicate that the cellular response to drugs can be altered by changes in both transport properties of the tissue and the CM interactions. By systematically investigating the effects of CC interactions and CM interactions, we can use mathematical models to delineate physical means of drug resistivity from a biologically driven resistance.
format Online
Article
Text
id pubmed-8823421
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Cambridge University Press
record_format MEDLINE/PubMed
spelling pubmed-88234212022-02-18 4168 Understanding ECM-Based Drug Resistivity in Breast Cancer Libring, Sarah Shinde, Aparna Boodaghidizaji, Miad Plummer, Alexandra Ardekani, Arezoo Wendt, Michael Solorio, Luis J Clin Transl Sci Precision Medicine OBJECTIVES/GOALS: Cell-cell (CC) and cell-matrix interactions (CM) are known to affect drug sensitivity of cancer cells, but are not effectively recapitulated using 2D platforms. This research aims to determine how cell and matrix interactions confer drug resistivity in 3 distinct culturing models: 2D (no CM/limited CC), 3D spheroids (CC) and 3D fibronectin (both). METHODS/STUDY POPULATION: We examined four breast cancer cell types. The cells were derived from a nonmetastatic primary tumor (HMLE-E2) or overt bone-metastasis (BM). Transglutaminase 2 (TGM2), a matrix crosslinking protein, is overexpressed in metastatic bone tumors and may play a key role in matrix-conferred drug resistivity. In a gain-of-function model, TGM2 was upregulated in HMLE-E2 cells and compared to shTGM2 knockdown BM cells. Growth rates were analyzed using metabolic activity over 8 days, and drug sensitivity to Neratinib (0-1000 nM) was analyzed via cell titer. To account for the different transport properties of the 3 distinct culture environments, we developed a mathematical model for each condition, allowing us to normalize the drug sensitivity results across models to effectively compare true biological resistivity. RESULTS/ANTICIPATED RESULTS: We observed that increased cellular levels of TGM2 significantly increase the growth rate and drug resistivity of cells on fibronectin matrices. Interestingly, in 2D cultures, TGM2 expression was correlated with higher Neratinib resistivity but did not affect growth rates. In spheroid models without a significant matrix component, that rely solely on cell-cell junctions, high levels of TGM2 were correlated with lower survival rates. Lower levels of TGM2 are correlated with a more epithelial phenotype, and using our mathematical model we have identified significant transport differences between high and low TGM2 spheroids. We theorize that the low TGM2 spheroids have denser packing, which lowers the rate of diffusion and, thus reduces the effective concentration of the drug to the majority of the cells. DISCUSSION/SIGNIFICANCE OF IMPACT: Our studies indicate that the cellular response to drugs can be altered by changes in both transport properties of the tissue and the CM interactions. By systematically investigating the effects of CC interactions and CM interactions, we can use mathematical models to delineate physical means of drug resistivity from a biologically driven resistance. Cambridge University Press 2020-07-29 /pmc/articles/PMC8823421/ http://dx.doi.org/10.1017/cts.2020.346 Text en © The Association for Clinical and Translational Science 2020 https://creativecommons.org/licenses/by/4.0/This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Precision Medicine
Libring, Sarah
Shinde, Aparna
Boodaghidizaji, Miad
Plummer, Alexandra
Ardekani, Arezoo
Wendt, Michael
Solorio, Luis
4168 Understanding ECM-Based Drug Resistivity in Breast Cancer
title 4168 Understanding ECM-Based Drug Resistivity in Breast Cancer
title_full 4168 Understanding ECM-Based Drug Resistivity in Breast Cancer
title_fullStr 4168 Understanding ECM-Based Drug Resistivity in Breast Cancer
title_full_unstemmed 4168 Understanding ECM-Based Drug Resistivity in Breast Cancer
title_short 4168 Understanding ECM-Based Drug Resistivity in Breast Cancer
title_sort 4168 understanding ecm-based drug resistivity in breast cancer
topic Precision Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8823421/
http://dx.doi.org/10.1017/cts.2020.346
work_keys_str_mv AT libringsarah 4168understandingecmbaseddrugresistivityinbreastcancer
AT shindeaparna 4168understandingecmbaseddrugresistivityinbreastcancer
AT boodaghidizajimiad 4168understandingecmbaseddrugresistivityinbreastcancer
AT plummeralexandra 4168understandingecmbaseddrugresistivityinbreastcancer
AT ardekaniarezoo 4168understandingecmbaseddrugresistivityinbreastcancer
AT wendtmichael 4168understandingecmbaseddrugresistivityinbreastcancer
AT solorioluis 4168understandingecmbaseddrugresistivityinbreastcancer